Anti-PD1-Induced Pneumonitis: Capturing the Hidden Enemy.
Anti-PD1 antibodies have led to a therapeutic shift in cancer treatment. Although classically described as "well tolerated," these drugs can lead to severe immune-related adverse events. Using CT scan imaging, Nishino and colleagues describe different radiologic patterns and their possible relation to severity of several cases of anti-PD1-induced pneumonitis. Clin Cancer Res; 22(24); 5956-8. ©2016 AACRSee related article by Nishino et al., p. 6051.
Drug Development Department, Gustave Roussy Comprehensive Cancer Center, Villejuif, France. EDUARDO.CASTANON-ALVAREZ@gustaveroussy.fr.
Eduardo
E
Castanon
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism; D011014:Pneumonia / Q000139:chemically induced* / Q000378:metabolism; D061026:Programmed Cell Death 1 Receptor / Q000378:metabolism*
D000911:Antibodies, Monoclonal; D061026:Programmed Cell Death 1 Receptor